Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings
about
Oral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: opportunities and challengesClinical trials in low and middle-income countries - Successes and challengesEfficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks' follow-upInfluence of adverse drug reactions on treatment success: prospective cohort analysis of HIV-infected individuals initiating first-line antiretroviral therapy in IndiaPsychosocial predictors of non-adherence and treatment failure in a large scale multi-national trial of antiretroviral therapy for HIV: data from the ACTG A5175/PEARLS trialAssociation between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data.25-Hydroxyvitamin D insufficiency and deficiency is associated with HIV disease progression and virological failure post-antiretroviral therapy initiation in diverse multinational settingsEffects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.Effectiveness of first-line antiretroviral therapy in the IPEC cohort, Rio de Janeiro, Brazil.Addressing standards of care in resource-limited settings.Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapineWhat is the optimal first line antiretroviral therapy in resource-limited settings?Trends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003-2012 decade in Italy.Pre-antiretroviral therapy serum selenium concentrations predict WHO stages 3, 4 or death but not virologic failure post-antiretroviral therapy.Cost-effectiveness of genotype testing for primary resistance in BrazilOutcomes among HIV-1 infected individuals first starting antiretroviral therapy with concurrent active TB or other AIDS-defining disease.C-reactive protein (CRP), interferon gamma-inducible protein 10 (IP-10), and lipopolysaccharide (LPS) are associated with risk of tuberculosis after initiation of antiretroviral therapy in resource-limited settings.Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175).Systematic Literature Review and Meta-Analysis of Renal Function in Human Immunodeficiency Virus (HIV)-Infected Patients Treated with Atazanavir (ATV)-Based Regimens.Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial.Adherence to Early Antiretroviral Therapy: Results From HPTN 052, a Phase III, Multinational Randomized Trial of ART to Prevent HIV-1 Sexual Transmission in Serodiscordant CouplesPresence of Plasmodium falciparum DNA in Plasma Does Not Predict Clinical Malaria in an HIV-1 Infected PopulationTreatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period.CD4 Response Up to 5 Years After Combination Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Patients in Latin America and the Caribbean.A Randomized Comparison of Anthropomorphic Changes With Preferred and Alternative Efavirenz-Based Antiretroviral Regimens in Diverse Multinational SettingsPrevalence and risk factors of micronutrient deficiencies pre- and post-antiretroviral therapy (ART) among a diverse multicountry cohort of HIV-infected adults.Comparison of HBV-active HAART regimens in an HIV-HBV multinational cohort: outcomes through 144 weeks.Toxicity and clinical outcomes in patients with HIV on zidovudine and tenofovir based regimens: a retrospective cohort study.Concurrent Anemia and Elevated C-Reactive Protein Predicts HIV Clinical Treatment Failure, Including Tuberculosis, After Antiretroviral Therapy InitiationA Randomized, Double-Blind, Placebo-Controlled Clinical Trial of a Chemokine Receptor 5 (CCR5) Antagonist to Decrease the Occurrence of Immune Reconstitution Inflammatory Syndrome in HIV-Infection: The CADIRIS StudyPredicting resistance as indicator for need to switch from first-line antiretroviral therapy among patients with elevated viral loads: development of a risk score algorithmPre-cART Elevation of CRP and CD4+ T-Cell Immune Activation Associated With HIV Clinical Progression in a Multinational Case-Cohort StudyDifferences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trialPersistently Elevated C-Reactive Protein Level in the First Year of Antiretroviral Therapy, Despite Virologic Suppression, Is Associated With HIV Disease Progression in Resource-Constrained Settings.Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342).Changes in HIV-1 subtypes B and C genital tract RNA in women and men after initiation of antiretroviral therapy.5α-reduced progestogens ameliorate mood-related behavioral pathology, neurotoxicity, and microgliosis associated with exposure to HIV-1 Tat.Inflammation and Change in Body Weight With Antiretroviral Therapy Initiation in a Multinational Cohort of HIV-Infected AdultsRaltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study
P2860
Q27023352-CAB98CCB-2421-47E5-A839-AAB4F1EB19EFQ28074682-3C34635C-77C6-47CF-BE41-4DDA7B1AB6E0Q28538860-4B5A91C9-6A09-40DC-9EEB-AFDAFCCB87DDQ28540682-22BD0D95-9461-4A74-A406-23C82CAD0295Q28542529-C707F83A-4AA0-4B09-B81A-D4B1C2DC9A44Q30834094-B616C086-AF1F-4C10-8B31-4BF499A49ADCQ34076892-CE698F6E-FBC0-4781-B0FB-8D0820B5F3B1Q34086963-55478ED6-DDAF-46DD-BB7D-702F8203D9CCQ34134900-F580BA83-870C-4385-905B-5E1B7CEFEC95Q34153838-DA290E77-744A-4660-86E2-FA5A3374970FQ34214090-3DCA7E5C-F3AC-4FB7-A1D6-5C938DC1031AQ34250879-86D46C86-A282-44C7-81A5-9F06ABEC00B1Q34384142-CA555E90-ADAC-434C-9138-2F8A45B5A099Q34468059-B41F8688-EB5B-4443-8D0B-9A82EC7E9852Q34578091-A4CC1B79-20F2-4807-90A2-8F7E1D73F0F4Q34964120-8689748E-771B-4CC9-B8B5-C297FE8E8690Q35082553-A3E0BC3D-B6B1-4140-B23F-E8CBD82CDB5DQ35125891-1B9045ED-4FA8-4091-95D7-13FAEB14D74FQ35170350-82F5D64F-37FF-424E-8CE9-61D138620F56Q35566732-52ABC166-71C5-4E9E-941D-1F92A468528DQ35588149-B428A9E6-282D-48F5-98F5-01AF7668E293Q35652641-AE22E32B-09D2-426F-9B2D-40A191EC3810Q35656242-E932662D-E6D7-49F8-875A-99D92B3CE40DQ35827900-DBE536D9-737A-40F9-9806-A7525AB74A53Q35837756-B11A870B-D1BC-4B94-B900-9568CF61AD09Q35881469-63FE375A-B5D6-4163-91DE-A38696B1A395Q35935280-14B0ACF7-929F-49BF-82C4-D992395BB439Q35949791-ACAA97A8-A17C-4F34-BFCF-2D2F16F1AC61Q35975345-965DBBF1-35FB-421C-ACDC-862C611CC637Q35975559-47DB72E6-5137-40D9-8583-8EE28B3AF2EEQ36041006-046CBCDF-AFC9-4E21-9200-F75A081D1B42Q36050916-3062B23B-B13C-400D-99E9-69F163255838Q36068935-AC18B039-A7CC-4DD7-AEE9-81908C4C5581Q36157703-21AB9E54-8D43-4771-9124-DDB8971653C2Q36654575-E77122DE-7DAB-4222-B879-44CEF4861C46Q36901492-C1B06F2E-9841-4271-BEC1-8770CA59CBC9Q36946237-CA5AFA3C-AF57-417B-AEC3-73B779E1668BQ36984167-D67EF5AE-F99D-4169-9CDC-79A64B3CE0C2Q37003062-FAD8E347-DD63-465F-8821-1A240B9028D3Q37021431-187CAA18-CDCB-451E-8DA3-07FDB7999274
P2860
Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Efficacy and safety of three a ...... diverse multinational settings
@ast
Efficacy and safety of three a ...... diverse multinational settings
@en
Efficacy and safety of three a ...... diverse multinational settings
@en-gb
Efficacy and safety of three a ...... diverse multinational settings
@nl
type
label
Efficacy and safety of three a ...... diverse multinational settings
@ast
Efficacy and safety of three a ...... diverse multinational settings
@en
Efficacy and safety of three a ...... diverse multinational settings
@en-gb
Efficacy and safety of three a ...... diverse multinational settings
@nl
altLabel
Efficacy and Safety of Three A ...... Diverse Multinational Settings
@en
prefLabel
Efficacy and safety of three a ...... diverse multinational settings
@ast
Efficacy and safety of three a ...... diverse multinational settings
@en
Efficacy and safety of three a ...... diverse multinational settings
@en-gb
Efficacy and safety of three a ...... diverse multinational settings
@nl
P2093
P2860
P50
P3181
P1433
P1476
Efficacy and safety of three a ...... diverse multinational settings
@en
P2093
Ana I Martinez
Ann Walawander
Apsara Nair
Cynthia Riviere
James F Rooney
James Gita Hakim
Johnstone Kumwenda
Jonathan Uy
Jorge Sanchez
Karin L Klingman
P2860
P304
P3181
P356
10.1371/JOURNAL.PMED.1001290
P407
P577
2012-01-01T00:00:00Z